



Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer

Editorial Office

Translational Lung Cancer Research

Correspondence to: Editorial Office. Translational Lung Cancer Research. Email: editor@tlcr.org.

Submitted Mar 20, 2022. Accepted for publication Mar 21, 2022.

doi: 10.21037/tlcr-2022-1

View this article at: <https://dx.doi.org/10.21037/tlcr-2022-1>

Erratum to: *Transl Lung Cancer Res* 2021;10:4368-79

The article (1) titled “Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer” (doi: 10.21037/tlcr-21-682), unfortunately contained a mistake in the first affiliation of Zhen Wang^{1,2} and Yong Song^{1,5#}. The correct authors’ affiliation 1 is listed below:

¹The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.

Therefore, the correct author information is as follows:

Zhen Wang^{1,2}, Lingyun Wei³, Jing Li², Han Zhou², Si Li⁴, Dongsheng Chen⁴, Yangyang Yu⁴, Lele Zhao⁴, Xixu Zhu^{2#}, Yong Song^{1,5#}

¹The First School of Clinical Medicine, Southern Medical University, Guangzhou, China; ²Department of Radiation Oncology, Jinling Hospital, Nanjing, China; ³Department of Cardiothoracic Surgery, School of Medicine, Nanjing University/General Hospital of Eastern Theater Command, Nanjing, China; ⁴The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China; ⁵Department of Respiratory and Critical Care Medicine, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing, China

The authors regret the error.

Click [here](#) to view the updated version of the article.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Wang Z, Wei L, Li J, et al. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer. *Transl Lung Cancer Res* 2021;10:4368-79.

Cite this article as: Editorial Office. Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer. *Transl Lung Cancer Res* 2022;11(3):504-505. doi: 10.21037/tlcr-2022-1